Literature DB >> 23277720

A Comparative Study of Bone Scan Findings and Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma.

Meera S Ghadge1, Purva P Naik, Bijaynath P Tiwari, Ruprekha M Hegde, Tanaji J Matale.   

Abstract

Breast cancer is one of the most frequent malignancies in the world. Available staging procedures to detect breast cancer are bone scan, chest X-ray, liver ultrasonography, computerized tomography, estimation of tumor markers like carbohydrate antigen (CA15-3) and carcino embryonic antigen. These procedures are expensive and may not be required in all cases. Out of 70 patients studied, 55 had normal CA15-3 and 15 had elevated levels of Ca15-3. Eight (14.5%) of the 55 patients with normal CA15-3 had abnormal bone scan. Fifteen patients had CA15-3 levels above the normal range and among these 9 (60%) had abnormal bone scan. While prime facie it would appear that a high level of CA15-3 correlate with abnormal bone scan, it is also true that the numbers are small at present and conclusions about the validity of CA15-3 as marker of bone metastasis may be premature.

Entities:  

Keywords:  Bone scan; Breast cancer; CA15-3; Metastasis; Tumor marker

Year:  2011        PMID: 23277720      PMCID: PMC3286586          DOI: 10.1007/s12291-011-0168-5

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  17 in total

1.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis.

Authors:  E F Solomayer; I J Diel; G C Meyberg; C Gollan; G Bastert
Journal:  Breast Cancer Res Treat       Date:  2000-02       Impact factor: 4.872

Review 2.  [Bone scintigraphy in breast cancer: a ten-year follow up study].

Authors:  M Rajtár; O Esik; L Almási; L Csernay
Journal:  Orv Hetil       Date:  1990-09-02       Impact factor: 0.540

3.  Comparison of bone scan with carbohydrate antigen 15-3 for evaluation of bone metastasis of brest cancer.

Authors:  M Mohammadzadeh; H Alikhah; A G A Zareh
Journal:  Pak J Biol Sci       Date:  2010-02-15

4.  Interference in immunoassays by human anti-mouse antibodies.

Authors:  R J Kinders; G M Hass
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

Review 5.  What do breast cancer patients benefit from staging bone scintigraphy?

Authors:  M Koizumi; M Yoshimoto; F Kasumi; E Ogata
Journal:  Jpn J Clin Oncol       Date:  2001-06       Impact factor: 3.019

Review 6.  Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.

Authors:  Wende Kozlow; Theresa A Guise
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-04       Impact factor: 2.673

7.  Relationship between bone scintigraphy and tumor markers in patients with breast cancer.

Authors:  Mustafa Yildiz; Baha Oral; Mehmet Bozkurt; Azem Cobaner
Journal:  Ann Nucl Med       Date:  2004-09       Impact factor: 2.668

8.  Reappraisal of the baseline bone scan in breast cancer.

Authors:  R E Coleman; R D Rubens; I Fogelman
Journal:  J Nucl Med       Date:  1988-06       Impact factor: 10.057

9.  'For' or 'against' bone scintigraphy of patients with breast cancer.

Authors:  S G Derimanov
Journal:  Nucl Med Commun       Date:  1987-02       Impact factor: 1.690

10.  Value of routine 99mTc-MDP bone scintigraphy in the detection of occult skeletal metastases in women with primary breast cancer.

Authors:  C H Yip; M Paramsothy
Journal:  Breast       Date:  1999-10       Impact factor: 4.380

View more
  2 in total

1.  Evaluation of a newly developed quantitative determination kit for tumor marker CA15-3 with chemiluminescent assay.

Authors:  Peihua Li; Huiming Ye; Jiangwu Liu; Hongwei Jin; Yongzhi Lin; Shuidi Yan; Yang Yu; Lei Gao; Feihai Xu; Zhongying Zhang
Journal:  J Clin Lab Anal       Date:  2017-02-23       Impact factor: 2.352

2.  Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.

Authors:  Gangping Wang; Yan Qin; Junxi Zhang; Jinhui Zhao; Yun'ai Liang; Zuofeng Zhang; Meihua Qin; Yanqing Sun
Journal:  Int J Mol Sci       Date:  2014-05-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.